You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePromethazine
Accession NumberDB01069  (APRD00601)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. [PubChem]
Structure
Thumb
Synonyms
(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(dimethylamino)Propyl]phenothiazine
N-(2'-dimethylamino-2'-Methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,α-trimethyl-10H-phenothiazine-10-ethanamine
Proazamine
Prometazina
Promethazine
Promethazinum
External Identifiers
  • Lilly 1516
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenergan Injectable 25mg/mlsolution25 mgintramuscular; intravenousAventis Pharma Inc1949-12-312005-08-01Canada
Promethazine HCl Inj 28.2mg/mlliquid28.2 mgintramuscular; intravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Promethazine HCl Inj USPsolution25 mgintramuscular; intravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Promethazine Hydrochloride Injection USPliquid25 mgintramuscular; intravenousSandoz Canada Incorporated1982-12-31Not applicableCanada
Promethazine Hydrochloride Injection, USPsolution25 mgintramuscular; intravenousMylan Pharmaceuticals Ulc1994-12-312015-11-03Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenadozsuppository12.5 mg/1rectalWatson Laboratories, Inc.2013-02-12Not applicableUs
Phenadozsuppository25 mg/1rectalWatson Laboratories, Inc.2013-04-03Not applicableUs
Phenadozsuppository25 mg/1rectalREMEDYREPACK INC.2013-05-14Not applicableUs
Phenadozsuppository12.5 mg/1rectalPd Rx Pharmaceuticals, Inc.2003-06-24Not applicableUs
Phenadozsuppository25 mg/1rectalPaddock Laboratories, Inc.2003-06-24Not applicableUs
Phenadozsuppository12.5 mg/1rectalActavis Pharma, Inc.2015-03-16Not applicableUs
Phenadozsuppository12.5 mg/1rectalPaddock Laboratories, Inc.2003-06-24Not applicableUs
Phenadozsuppository25 mg/1rectalActavis Pharma, Inc.2015-02-17Not applicableUs
Phenerganinjection50 mg/mLintramuscularWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Phenergansuppository50 mg/1rectalPrestium Pharma, Inc.2014-08-01Not applicableUs
Phenerganinjection, solution50 mg/mLintramuscularBaxter Healthcare Corporation2009-12-102015-12-29Us
Phenerganinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Phenergansuppository12.5 mg/1rectalPrestium Pharma, Inc.2014-08-01Not applicableUs
Phenerganinjection50 mg/mLintramuscularWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Phenergansuppository25 mg/1rectalPrestium Pharma, Inc.2014-08-01Not applicableUs
Phenerganinjection, solution25 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2009-12-102015-12-29Us
Phenerganinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazinetablet12.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-12-14Not applicableUs
Promethazineinjection25 mg/mLintramuscular; intravenousCardinal Health2002-08-22Not applicableUs
Promethazineinjection50 mg/mLintramuscularPhysicians Total Care, Inc.2002-08-22Not applicableUs
Promethazine HCltablet25 mg/1oralCardinal Health2011-06-21Not applicableUs
Promethazine Hydrochlorideinjection50 mg/mLintramuscularWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1975-12-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralSandoz Inc1975-12-19Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousX Gen Pharmaceuticals, Inc.2015-01-30Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralBlue Point Laboratories2014-01-13Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralAtlantic Biologicals Corps1982-11-15Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalPerrigo New York Inc2006-05-17Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMc Kesson Contract Packaging2011-09-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalPhysicians Total Care, Inc.2003-02-18Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralCardinal Health1982-11-15Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralClinical Solutions Wholesale1973-09-19Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2008-02-12Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralQualitest Pharmaceuticals2006-07-18Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralHeritage Pharmaceuticals Inc.2013-02-17Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralAmneal Pharmaceuticals2011-03-03Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralBlenheim Pharmacal, Inc.2015-09-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralRebel Distributors Corp2011-03-03Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralZydus Pharmaceuticals (USA) Inc.2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/301oralNorthwind Pharmaceuticals2014-05-20Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralPhysicians Total Care, Inc.2005-05-23Not applicableUs
Promethazine Hydrochlorideinjection50 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2005-09-29Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1982-11-15Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralWatson Laboratories, Inc.1973-09-19Not applicableUs
Promethazine Hydrochlorideinjection50 mg/mLintramuscularWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralTYA Pharmaceuticals1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMajor Pharmaceuticals2015-03-15Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalDispensing Solutions Inc.2003-12-19Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralRebel Distributors Corp1982-11-15Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralUnit Dose Services2012-07-17Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscularREMEDYREPACK INC.2014-02-18Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPreferred Pharmaceuticals, Inc.2013-04-24Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2013-03-25Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralA S Medication Solutions Llc2012-07-17Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousCardinal Health1973-09-19Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralSun Pharmaceutical Industries, Inc.2009-01-27Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralLiberty Pharmaceuticals, Inc.2012-07-17Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralbryant ranch prepack2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralAidarex Pharmaceuticals LLC2012-07-17Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMed Vantx, Inc.2006-07-18Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralApotheca, Inc1999-06-10Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2011-03-03Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralReady Meds2011-03-03Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralSandoz Inc1975-02-18Not applicableUs
Promethazine Hydrochlorideinjection, solution50 mg/mLintramuscular; intravenousX Gen Pharmaceuticals, Inc.2015-01-30Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralBlue Point Laboratories2014-01-13Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralRebel Distributors Corp1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMc Kesson Contract Packaging2012-02-02Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPhysicians Total Care, Inc.1995-08-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralCardinal Health2006-09-08Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralGolden State Medical Supply, Inc.2006-07-31Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2008-02-12Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralQualitest Pharmaceuticals2006-07-18Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralHeritage Pharmaceuticals Inc.2013-02-17Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralCadila Healthcare Limited2005-12-14Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralKvk Tech, Inc.2014-07-09Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralSTAT Rx USA LLC1973-09-19Not applicableUs
Promethazine Hydrochloridesolution6.25 mg/5mLoralPreferred Pharmaceuticals, Inc.2013-09-23Not applicableUs
Promethazine Hydrochloridetablet25 mg/301oralNorthwind Pharmaceuticals2014-05-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralDispensing Solutions, Inc.2006-04-26Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousDispensing Solutions Inc.2009-05-28Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralRebel Distributors Corp2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMylan Institutional Inc.2007-02-01Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2009-08-242015-12-29Us
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralPhysicians Total Care, Inc.1997-03-26Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralCardinal Health2012-08-15Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2014-10-14Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralWatson Laboratories, Inc.1973-09-21Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralAmneal Pharmaceuticals2011-03-03Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralBlenheim Pharmacal, Inc.2011-08-25Not applicableUs
Promethazine Hydrochloridesuppository12.5 mg/1rectalRenaissance Pharma, Inc.2014-08-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralbryant ranch prepack1973-09-19Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralAidarex Pharmaceuticals LLC2012-07-17Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralDispensing Solutions, Inc.2006-07-18Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralSTAT Rx USA LLC2006-07-18Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2011-03-03Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralPreferred Pharmaceuticals Inc.2015-08-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralA S Medication Solutions Llc2012-07-17Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousCardinal Health1973-09-19Not applicableUs
Promethazine Hydrochloridesolution6.25 mg/5mLoralSun Pharmaceutical Industries, Inc.2009-03-13Not applicableUs
Promethazine Hydrochlorideinjection50 mg/mLintramuscularWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochlorideinjection50 mg/mLintramuscularWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralReady Meds2011-03-03Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMajor Pharmaceuticals2008-05-09Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralAmerican Health Packaging2013-07-19Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralRebel Distributors Corp2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-28Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2009-12-102015-12-29Us
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2013-05-30Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousCardinal Health1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralGolden State Medical Supply, Inc.2006-07-31Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2008-05-20Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralProficient Rx LP2009-01-27Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2002-10-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2012-08-28Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralCadila Healthcare Limited2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralKvk Tech, Inc.2014-07-09Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2008-02-12Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPreferred Pharmaceuticals, Inc.1973-09-19Not applicableUs
Promethazine Hydrochloridesuppository12.5 mg/1rectalTaro Pharmaceuticals U.S.A., Inc.2015-06-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralSun Pharmaceutical Industries, Inc.2009-01-27Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralAmneal Pharmaceuticals2011-03-03Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralBlenheim Pharmacal, Inc.2010-03-30Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalRenaissance Pharma, Inc.2014-08-01Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralNorthwind Pharmaceuticals2014-06-01Not applicableUs
Promethazine Hydrochloridesolution6.25 mg/5mLoralPreferred Pharmaceuticals, Inc.2013-11-132015-12-29Us
Promethazine Hydrochlorideinjection, solution50 mg/mLintramuscularGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2000-02-29Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2008-02-12Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2015-05-15Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralQualitest Pharmaceuticals2006-04-26Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralbryant ranch prepack2011-03-03Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousX Gen Pharmaceuticals, Inc.2011-05-02Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralBlue Point Laboratories2014-01-13Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralSTAT Rx USA LLC1973-09-19Not applicableUs
Promethazine Hydrochloridesuppository12.5 mg/1rectalPerrigo New York Inc2006-06-27Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralLife Line Home Care Services, Inc.2006-07-18Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/1intramuscularREMEDYREPACK INC.2013-04-11Not applicableUs
Promethazine Hydrochlorideinjection, solution50 mg/mLintramuscular; intravenousCardinal Health2011-05-02Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralClinical Solutions Wholesale2009-01-27Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralGolden State Medical Supply, Inc.2006-07-31Not applicableUs
Promethazine Hydrochlorideinjection25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1973-09-19Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralTYA Pharmaceuticals2005-12-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralMajor Pharmaceuticals2011-07-14Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralAmerican Health Packaging2013-07-19Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalRebel Distributors Corp2003-06-30Not applicableUs
Promethazine Hydrochloridesolution6.25 mg/5mLoralHi Tech Pharmacal Co., Inc.1998-09-25Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2013-09-19Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralPhysicians Total Care, Inc.1994-12-19Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousCardinal Health2010-01-26Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralCardinal Health2011-03-03Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralSun Pharmaceutical Industries, Inc.2009-01-27Not applicableUs
Promethazine Hydrochlorideinjection, solution25 mg/mLintramuscular; intravenousHospira, Inc.2009-10-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-27Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralProficient Rx LP1982-11-15Not applicableUs
Promethazine Hydrochlorideinjection, solution50 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2002-10-01Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralTris Pharma Inc2012-08-03Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralCadila Healthcare Limited2005-12-14Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralKvk Tech, Inc.2014-07-09Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalPd Rx Pharmaceuticals, Inc.2006-05-17Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralPreferred Pharmaceuticals, Inc.2014-01-02Not applicableUs
Promethazine Hydrochloridesuppository25 mg/1rectalTaro Pharmaceuticals U.S.A., Inc.2015-06-01Not applicableUs
Promethazine Hydrochloridesyrup6.25 mg/5mLoralA S Medication Solutions Llc2006-04-26Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralQualitest Pharmaceuticals2006-07-18Not applicableUs
Promethazine Hydrochloridesolution6.25 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2009-12-30Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralBlenheim Pharmacal, Inc.2010-05-17Not applicableUs
Promethazine Hydrochloridesuppository50 mg/1rectalRenaissance Pharma, Inc.2014-08-01Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralZydus Pharmaceuticals (USA) Inc.2005-12-14Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralHeritage Pharmaceuticals Inc.2013-02-17Not applicableUs
Promethazine Hydrochloridetablet12.5 mg/1oralNorthwind Pharmaceuticals2014-03-03Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralDIRECT RX2016-02-18Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralH.J. Harkins Company, Inc.2005-12-14Not applicableUs
Promethazine Hydrochloridesuppository12.5 mg/1rectalPhysicians Total Care, Inc.2003-05-20Not applicableUs
Promethazine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2008-05-20Not applicableUs
Promethazine Hydrochloridetablet25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Promethegansuppository25 mg/1rectalH.J. Harkins Company, Inc.2002-02-28Not applicableUs
Promethegansuppository25 mg/1rectalPd Rx Pharmaceuticals, Inc.2002-02-28Not applicableUs
Promethegansuppository50 mg/1rectalG&W Laboratories, Inc.1987-08-31Not applicableUs
Promethegansuppository25 mg/1rectalREMEDYREPACK INC.2013-06-04Not applicableUs
Promethegansuppository25 mg/1rectalG&W Laboratories, Inc.2002-02-28Not applicableUs
Promethegansuppository50 mg/1rectalPhysicians Total Care, Inc.1996-06-17Not applicableUs
Promethegansuppository25 mg/1rectalRebel Distributors Corp2002-02-05Not applicableUs
Promethegansuppository12.5 mg/1rectalG&W Laboratories, Inc.2004-02-28Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Histantil Tab 25mgtablet25 mgoralPharmascience Inc1983-12-31Not applicableCanada
Histantil Tab 50mgtablet50 mgoralPharmascience Inc1983-12-31Not applicableCanada
Phenergan 50tablet50 mgoralColumbia Laboratories Canada Inc1996-12-312002-07-17Canada
Phenergan Cream 2%cream2 %topicalColumbia Laboratories Canada Inc1996-07-302007-07-24Canada
Phenergan Cream 2%cream2 %topicalRhone Poulenc Rorer Consumer Inc.1993-12-311997-08-13Canada
Phenergan Syrup 10mg/5mlsyrup10 mgoralRhone Poulenc Rorer Consumer Inc.1993-12-311996-09-09Canada
Phenergan Tablet 10mgtablet10 mgoralRhone Poulenc Rorer Consumer Inc.1993-12-311997-08-13Canada
Phenergan Tablet 25mgtablet25 mgoralRhone Poulenc Rorer Consumer Inc.1993-12-311997-08-13Canada
Phenergan Tablet 25mgtablet25 mgoralNovartis Consumer Health Canada Inc.1996-12-311999-07-21Canada
Phenergan Tablet 50mgtablet50 mgoralRhone Poulenc Rorer Consumer Inc.1992-12-311997-08-13Canada
PMS-promethazine Syr 10mg/5mlsyrup10 mgoralPharmascience Inc1984-12-31Not applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Promethazine HClinjection, solution.5 mg/mLintravenousCantrell Drug Company2014-05-29Not applicableUs
Promethazine HClinjection, solution1 mg/mLintravenousCantrell Drug Company2014-05-27Not applicableUs
Promethazine HClinjection, solution.625 mg/mLintravenousCantrell Drug Company2014-05-27Not applicableUs
International Brands
NameCompany
AvomineNot Available
FarganNot Available
FarganesseNot Available
LergiganNot Available
ProthiazineNot Available
ReceptozineNot Available
RomerganNot Available
Brand mixtures
NameLabellerIngredients
Dextromethorphan Hydrobromide and Promethazine HydrochlorideAtlantic Biologicals Corps
Meperidine Hydrochloride and Promethazine HydrochlorideEci Pharmaceuticals Llc
Promatussin DM Adult Formula SyrWyeth Ayerst Canada Inc.
Promatussin DM Children FormulaWyeth Ltd.
Prometh With CodeineActavis Mid Atlantic LLC
Prometh With DextromethorphanActavis Mid Atlantic LLC
Promethazine DMQualitest Pharmaceuticals
Promethazine HCl, Phenylephrine HCl, Codeine PhosphateAmneal Pharmaceuticals of New York, LLC
Promethazine Hydrochloride and Codeine PhosphatePharmaceutical Associates, Inc.
Promethazine Hydrochloride and Dextomethorphan HydrobromideAmneal Pharmaceuticals
Promethazine Hydrochloride and Dextromethorphan HydrobromideRebel Distributors Corp
Promethazine Hydrochloride and Phenylephrine HydrochlorideActavis Mid Atlantic LLC
Promethazine Hydrochloride Phenylephrine Hydrochloride and Codeine Phosphatebryant ranch prepack
Promethazine Hydrochloride, Phenylephrine Hydrochloride, and Codeine PhosphateHi Tech Pharmacal Co., Inc.
Promethazine VcQualitest Pharmaceuticals
Promethazine Vc With CodeineActavis Mid Atlantic LLC
Promethazine With CodeineQualitest Pharmaceuticals
Promethazine With Codeine CoughMorton Grove Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Promethazine hydrochloride
58-33-3
Thumb
  • InChI Key: XXPDBLUZJRXNNZ-UHFFFAOYNA-N
  • Monoisotopic Mass: 320.111397079
  • Average Mass: 320.88
DBSALT000427
Categories
UNIIFF28EJQ494
CAS number60-87-7
WeightAverage: 284.419
Monoisotopic: 284.13471934
Chemical FormulaC17H20N2S
InChI KeyInChIKey=PWWVAXIEGOYWEE-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
IUPAC Name
dimethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine
SMILES
CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of allergic disorders, and nausea/vomiting.
PharmacodynamicsPromethazine, a phenothiazine, is an H1-antagonist with anticholinergic, sedative, and antiemetic effects and some local anesthetic properties. Promethazine is used as an antiemetic or to prevent motion sickness.
Mechanism of actionLike other H1-antagonists, promethazine competes with free histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. The relief of nausea appears to be related to central anticholinergic actions and may implicate activity on the medullary chemoreceptor trigger zone.
Related Articles
AbsorptionOn average, 88% of a promethazine dose is absorbed after oral administration; however, the absolute bioavailability is only 25% because of first-pass clearance.
Volume of distributionNot Available
Protein binding93%
Metabolism

Hepatic

Route of eliminationPromethazine hydrochloride is metabolized in the liver, with the sulfoxides of promethazine and N-desmethylpromethazine being the predominant metabolites appearing in the urine.
Half life16-19 hours
ClearanceNot Available
ToxicitySymptoms of overdose include mild depression of the central nervous system and cardiovascular system to profound hypotension, respiratory depression, unconsciousness, and sudden death. Other reported reactions include hyperreflexia, hypertonia, ataxia, athetosis, and extensor-plantar reflexes (Babinski reflex). LD50=55mg/kg (I.V. in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9832
Blood Brain Barrier+0.9855
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8157
P-glycoprotein inhibitor IInhibitor0.8408
P-glycoprotein inhibitor IINon-inhibitor0.6473
Renal organic cation transporterInhibitor0.5156
CYP450 2C9 substrateNon-substrate0.7736
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5338
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9341
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.567
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9088
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6959 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9786
hERG inhibition (predictor II)Inhibitor0.7661
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Suppositoryrectal12.5 mg/1
Suppositoryrectal25 mg/1
Creamtopical2 %
Solutionintramuscular; intravenous25 mg
Syruporal10 mg
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Injection, solutionintravenous.5 mg/mL
Injection, solutionintravenous.625 mg/mL
Injection, solutionintravenous1 mg/mL
Liquidintramuscular; intravenous28.2 mg
Injectionintramuscular25 mg/mL
Injectionintramuscular50 mg/mL
Injectionintramuscular; intravenous25 mg/mL
Injectionintramuscular; intravenous50 mg/mL
Injection, solutionintramuscular25 mg/1
Injection, solutionintramuscular50 mg/mL
Injection, solutionintramuscular; intravenous25 mg/mL
Injection, solutionintramuscular; intravenous50 mg/mL
Solutionoral6.25 mg/5mL
Syruporal6.25 mg/5mL
Tabletoral12.5 mg/1
Tabletoral25 mg/301
Tabletoral25 mg/1
Tabletoral50 mg/1
Syruporal
Solutionoral
Liquidintramuscular; intravenous25 mg
Liquidoral
Suppositoryrectal50 mg/1
Prices
Unit descriptionCostUnit
Promethegan 12 50 mg Suppository Box101.64USD box
Phenergan 12 50 mg Suppository Box80.16USD box
Phenergan 12 25 mg Suppository Box62.59USD box
Promethegan 12 25 mg Suppository Box62.27USD box
Promethazine HCl 12 50 mg Suppository Box60.94USD box
Phenergan 12 12.5 mg Suppository Box54.58USD box
Phenergan 25 mg suppository8.32USD suppository
Promethegan 50 mg suppository8.14USD suppository
Phenergan 12.5 mg suppository7.94USD suppository
Phenergan 50 mg suppository7.39USD suppository
Promethazine 50 mg suppository4.88USD suppository
Promethegan 25 mg suppository4.62USD suppository
Phenadoz 25 mg suppository4.45USD suppository
Promethazine 25 mg suppository4.32USD suppository
Promethegan 12.5 mg suppository4.02USD suppository
Promethazine HCl 12.5 mg Suppository4.0USD suppository
Phenadoz 12.5 mg suppository3.89USD suppository
Phenergan 25 mg/ml ampul3.84USD ml
Promethazine 12.5 mg suppository3.82USD suppository
Phenergan 50 mg/ml ampul3.68USD ml
Promethazine HCl 50 mg/ml Solution 1ml Ampule2.8USD ampule
Promethazine 50 mg/ml ampul2.25USD ml
Promethazine hcl powder2.14USD g
Promethazine 25 mg/ml ampul1.1USD ml
Promethazine 25 mg/ml1.06USD ml
Promethazine HCl 50 mg tablet0.81USD tablet
Promethazine 50 mg tablet0.78USD tablet
Promethazine HCl 25 mg tablet0.73USD tablet
Phenergan 25 mg tablet0.62USD tablet
Promethazine 25 mg tablet0.51USD tablet
Promethazine 12.5 mg tablet0.49USD tablet
Promethazine-DM 6.25-15 mg/5ml Syrup0.18USD ml
Promethazine HCl 6.25 mg/5ml Syrup0.11USD ml
Promethazine VC Plain 6.25-5 mg/5ml Syrup0.09USD ml
Promethazine-Codeine 6.25-10 mg/5ml Syrup0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point60 °CPhysProp
boiling point190-192 °C at 3.00E+00 mm HgPhysProp
water solubility15.6 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.81HANSCH,C ET AL. (1995)
logS-4.26ADME Research, USCD
pKa9.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0245 mg/mLALOGPS
logP4.52ALOGPS
logP4.29ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)9.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity88.5 m3·mol-1ChemAxon
Polarizability32.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.88 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-9210000000-7167670dff3395a6ade2View in MoNA
References
Synthesis Reference

DrugSyn.org

US2530451
General References
  1. Peters RJ Jr, Kelder SH, Markham CM, Yacoubian GS Jr, Peters LA, Ellis A: Beliefs and social norms about codeine and promethazine hydrochloride cough syrup (CPHCS) onset and perceived addiction among urban Houstonian adolescents: an addiction trend in the city of lean. J Drug Educ. 2003;33(4):415-25. [PubMed:15237866 ]
External Links
ATC CodesV03AB05R06AD02R06AD52D04AA10
AHFS Codes
  • 04:04.12
PDB EntriesNot Available
FDA labelDownload (93.4 KB)
MSDSDownload (74.8 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Promethazine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Promethazine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Promethazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Promethazine.
AbirateroneThe metabolism of Promethazine can be decreased when combined with Abiraterone.
AcebutololPromethazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Promethazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Promethazine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Promethazine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Promethazine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Promethazine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Promethazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Promethazine.
AlfentanilPromethazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Promethazine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Promethazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Promethazine.
AlphacetylmethadolPromethazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Promethazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promethazine.
AlprenololPromethazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Promethazine.
AmiodaronePromethazine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Promethazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Promethazine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Promethazine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Promethazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Promethazine.
AmodiaquineThe serum concentration of Promethazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Promethazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Promethazine is combined with Amperozide.
AmphetamineAmphetamine may decrease the sedative activities of Promethazine.
AnagrelidePromethazine may increase the QTc-prolonging activities of Anagrelide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Promethazine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Promethazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Promethazine.
ArotinololPromethazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Promethazine.
ArtemetherThe serum concentration of Promethazine can be increased when it is combined with Artemether.
ArtemetherPromethazine may increase the QTc-prolonging activities of Artemether.
ArtesunateThe serum concentration of Promethazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Promethazine.
AsenapineThe risk or severity of adverse effects can be increased when Promethazine is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Promethazine.
AtenololPromethazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Promethazine can be decreased when combined with Atomoxetine.
AtovaquoneThe serum concentration of Promethazine can be increased when it is combined with Atovaquone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Promethazine.
AzaperoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Azaperone.
AzelastinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Promethazine.
AzithromycinPromethazine may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Promethazine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Promethazine.
BedaquilinePromethazine may increase the QTc-prolonging activities of Bedaquiline.
BefunololPromethazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Promethazine.
BenzphetamineBenzphetamine may decrease the sedative activities of Promethazine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Promethazine.
Benzylpenicilloyl PolylysinePromethazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Promethazine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Promethazine.
BetaxololPromethazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Promethazine can be decreased when combined with Betaxolol.
BevantololPromethazine may increase the hypotensive activities of Bevantolol.
BezitramidePromethazine may increase the hypotensive activities of Bezitramide.
BifeprunoxThe risk or severity of adverse effects can be increased when Promethazine is combined with Bifeprunox.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololPromethazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Promethazine.
BopindololPromethazine may increase the hypotensive activities of Bopindolol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Promethazine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Promethazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Promethazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
BrimonidineThe risk or severity of adverse effects can be increased when Promethazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Promethazine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Promethazine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Promethazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Promethazine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Promethazine.
BufuralolPromethazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Promethazine.
BupranololPromethazine may increase the hypotensive activities of Bupranolol.
BuprenorphinePromethazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Promethazine.
BupropionThe metabolism of Promethazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Promethazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promethazine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Promethazine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Promethazine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Promethazine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Promethazine.
ButorphanolPromethazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Promethazine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Promethazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promethazine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Promethazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Promethazine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Promethazine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Promethazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Promethazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Promethazine.
CarfentanilPromethazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Promethazine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Promethazine.
CariprazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Promethazine.
CarteololPromethazine may increase the hypotensive activities of Carteolol.
CarvedilolPromethazine may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Promethazine can be decreased when combined with Celecoxib.
CeliprololPromethazine may increase the hypotensive activities of Celiprolol.
CeritinibPromethazine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Promethazine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Promethazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Promethazine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Promethazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Promethazine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Promethazine.
ChloroquineThe serum concentration of Promethazine can be increased when it is combined with Chloroquine.
ChloroquinePromethazine may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Promethazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Promethazine can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Promethazine.
CholecalciferolThe metabolism of Promethazine can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Promethazine.
CimetidineThe metabolism of Promethazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Promethazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Promethazine.
CiprofloxacinPromethazine may increase the QTc-prolonging activities of Ciprofloxacin.
CisapridePromethazine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Promethazine.
CitalopramThe risk or severity of adverse effects can be increased when Promethazine is combined with Citalopram.
CitalopramThe metabolism of Promethazine can be decreased when combined with Citalopram.
ClarithromycinPromethazine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Promethazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Promethazine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Promethazine.
ClobazamThe metabolism of Promethazine can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Promethazine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Promethazine.
ClomipramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clomipramine.
ClomipramineThe metabolism of Promethazine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Promethazine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Promethazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Promethazine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Promethazine.
ClopidogrelThe metabolism of Promethazine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Promethazine.
ClotrimazoleThe metabolism of Promethazine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clozapine.
ClozapineThe metabolism of Promethazine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Promethazine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Promethazine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Promethazine.
CodeinePromethazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Promethazine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Promethazine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Promethazine.
CrizotinibPromethazine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Promethazine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Promethazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Promethazine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Promethazine.
DabrafenibThe serum concentration of Promethazine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Promethazine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Promethazine.
DantroleneThe risk or severity of adverse effects can be increased when Promethazine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Promethazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Promethazine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Promethazine.
DapsoneThe serum concentration of Promethazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Promethazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Promethazine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Promethazine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Promethazine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Promethazine.
DelavirdineThe metabolism of Promethazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Promethazine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Promethazine.
DesipramineThe metabolism of Promethazine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Promethazine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Promethazine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Promethazine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Promethazine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Promethazine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Promethazine.
DextromoramidePromethazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Promethazine.
DextropropoxyphenePromethazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Promethazine.
DezocinePromethazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Promethazine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Promethazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Promethazine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Promethazine.
DifenoxinThe risk or severity of adverse effects can be increased when Promethazine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Promethazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Promethazine.
DihydrocodeinePromethazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promethazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Promethazine.
DihydroetorphinePromethazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Promethazine.
DihydromorphinePromethazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promethazine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Promethazine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Promethazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Promethazine.
DiphenhydramineThe metabolism of Promethazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Diphenhydramine.
DiphenoxylatePromethazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Promethazine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Promethazine.
DisopyramidePromethazine may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Promethazine.
DofetilidePromethazine may increase the QTc-prolonging activities of Dofetilide.
DolasetronPromethazine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Promethazine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Promethazine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Promethazine.
DoxepinThe risk or severity of adverse effects can be increased when Promethazine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Promethazine.
DoxorubicinThe metabolism of Promethazine can be decreased when combined with Doxorubicin.
DoxycyclineThe serum concentration of Promethazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
DoxylamineThe risk or severity of adverse effects can be increased when Promethazine is combined with Doxylamine.
DPDPEPromethazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Promethazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
DronedaronePromethazine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Promethazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Promethazine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Promethazine.
DuloxetineThe metabolism of Promethazine can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Promethazine is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Promethazine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Promethazine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Promethazine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Promethazine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Promethazine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Promethazine.
EliglustatPromethazine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Promethazine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Promethazine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Promethazine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Promethazine.
EpinephrinePromethazine may decrease the vasoconstricting activities of Epinephrine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promethazine.
ErgonovineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promethazine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Promethazine.
ErythromycinPromethazine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Promethazine is combined with Escitalopram.
EsmololPromethazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Promethazine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Promethazine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Promethazine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Promethazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promethazine.
EthanolPromethazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Promethazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Promethazine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Promethazine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Promethazine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Promethazine.
EthylmorphinePromethazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Promethazine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Promethazine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Promethazine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Promethazine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Promethazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Promethazine.
EtorphinePromethazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Promethazine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Promethazine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Promethazine.
EzogabineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Promethazine.
FencamfamineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fenfluramine.
FentanylPromethazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promethazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promethazine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Promethazine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Promethazine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Promethazine.
FlecainidePromethazine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Promethazine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Promethazine.
FlunarizineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Promethazine.
FluoxetineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluoxetine.
FluoxetineThe metabolism of Promethazine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Promethazine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Promethazine.
FluspirileneThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Promethazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Promethazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Promethazine can be decreased when combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Promethazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Promethazine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Promethazine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Promethazine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Promethazine is combined with gabapentin enacarbil.
Gadobenic acidPromethazine may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Promethazine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Promethazine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Promethazine.
GemifloxacinPromethazine may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Promethazine.
GoserelinPromethazine may increase the QTc-prolonging activities of Goserelin.
GranisetronPromethazine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Promethazine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Promethazine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Promethazine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Promethazine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Promethazine.
HalofantrineThe serum concentration of Promethazine can be increased when it is combined with Halofantrine.
HaloperidolThe risk or severity of adverse effects can be increased when Promethazine is combined with Haloperidol.
HaloperidolThe metabolism of Promethazine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Promethazine.
HeroinPromethazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Promethazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Promethazine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.
HydrocodonePromethazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Promethazine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Promethazine.
HydromorphonePromethazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Promethazine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Promethazine.
HydroxychloroquineThe serum concentration of Promethazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Promethazine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Promethazine.
IbutilidePromethazine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Promethazine.
IloperidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Promethazine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Promethazine.
ImipramineThe metabolism of Promethazine can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Promethazine.
IndalpineThe risk or severity of adverse effects can be increased when Promethazine is combined with Indalpine.
IndenololPromethazine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Promethazine.
IndinavirThe metabolism of Promethazine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Promethazine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Promethazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Promethazine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Promethazine.
IsoniazidThe metabolism of Promethazine can be decreased when combined with Isoniazid.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Promethazine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Promethazine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Promethazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Promethazine.
KetobemidonePromethazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Promethazine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Promethazine.
KetoconazoleThe metabolism of Promethazine can be decreased when combined with Ketoconazole.
LabetalolPromethazine may increase the hypotensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Promethazine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Promethazine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Promethazine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Promethazine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Promethazine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Promethazine.
LenvatinibPromethazine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolidePromethazine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Promethazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Promethazine.
LevobunololPromethazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Promethazine.
LevocabastineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Promethazine is combined with Levodopa.
LevofloxacinPromethazine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetatePromethazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Promethazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Promethazine is combined with Levomilnacipran.
LevorphanolPromethazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Promethazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Promethazine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Promethazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Promethazine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Promethazine.
LithiumThe risk or severity of adverse effects can be increased when Promethazine is combined with Lithium.
LofentanilPromethazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Promethazine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Promethazine.
LopinavirPromethazine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Promethazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Promethazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promethazine.
LorcaserinThe metabolism of Promethazine can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Promethazine is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Promethazine.
LoxapineThe risk or severity of adverse effects can be increased when Promethazine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Promethazine is combined with Lu AA21004.
LumacaftorThe serum concentration of Promethazine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Promethazine can be increased when it is combined with Lumefantrine.
LumefantrinePromethazine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Promethazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Promethazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promethazine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Promethazine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Promethazine.
MefloquineThe serum concentration of Promethazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Promethazine.
MelperoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Melperone.
MephentermineMephentermine may decrease the sedative activities of Promethazine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Promethazine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine.
MesoridazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Promethazine.
MethadonePromethazine may increase the hypotensive activities of Methadone.
MethadoneThe metabolism of Promethazine can be decreased when combined with Methadone.
Methadyl AcetatePromethazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Promethazine.
MethamphetamineMethamphetamine may decrease the sedative activities of Promethazine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Promethazine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Promethazine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Promethazine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Promethazine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Promethazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Promethazine.
MethsuximideThe risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Promethazine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Promethazine.
MetipranololPromethazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Promethazine is combined with Metoclopramide.
MetoprololPromethazine may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Promethazine can be decreased when combined with Metoprolol.
MetyrosinePromethazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Promethazine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Promethazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Promethazine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Promethazine.
MilnacipranThe risk or severity of adverse effects can be increased when Promethazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Promethazine.
MirabegronThe metabolism of Promethazine can be decreased when combined with Mirabegron.
MirtazapinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Promethazine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Promethazine.
MoclobemideThe risk or severity of adverse effects can be increased when Promethazine is combined with Moclobemide.
MolindoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Molindone.
MorphinePromethazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Promethazine.
MoxifloxacinPromethazine may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Promethazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
NabiloneThe risk or severity of adverse effects can be increased when Promethazine is combined with Nabilone.
NadololPromethazine may increase the hypotensive activities of Nadolol.
NalbuphinePromethazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Promethazine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Promethazine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Promethazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Promethazine.
NefazodoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Promethazine.
NevirapineThe metabolism of Promethazine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Promethazine.
NicardipineThe metabolism of Promethazine can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Promethazine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Promethazine.
NilotinibThe metabolism of Promethazine can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Promethazine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Promethazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Promethazine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Promethazine.
NormethadonePromethazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Promethazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promethazine.
OfloxacinPromethazine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Promethazine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Promethazine.
OndansetronThe risk or severity of adverse effects can be increased when Promethazine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Promethazine.
OpiumPromethazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Promethazine.
OrphenadrinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Promethazine.
OsanetantThe risk or severity of adverse effects can be increased when Promethazine is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Promethazine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Promethazine.
OxprenololPromethazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Promethazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Promethazine.
OxycodonePromethazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Promethazine.
OxymorphonePromethazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Promethazine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Promethazine.
PaliperidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Promethazine.
PanobinostatPromethazine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Promethazine can be decreased when combined with Panobinostat.
ParaldehydePromethazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Promethazine.
ParoxetineThe risk or severity of adverse effects can be increased when Promethazine is combined with Paroxetine.
ParoxetineThe metabolism of Promethazine can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Promethazine.
Peginterferon alfa-2bThe serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPromethazine may increase the hypotensive activities of Penbutolol.
PentamidinePromethazine may increase the QTc-prolonging activities of Pentamidine.
PentazocinePromethazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promethazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Promethazine.
PerampanelThe risk or severity of adverse effects can be increased when Promethazine is combined with Perampanel.
PerflutrenPromethazine may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Promethazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Perphenazine.
PethidinePromethazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Promethazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promethazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Promethazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Promethazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Promethazine.
PhenterminePhentermine may decrease the sedative activities of Promethazine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Promethazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Promethazine.
PimozideThe risk or severity of adverse effects can be increased when Promethazine is combined with Pimozide.
PindololPromethazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Promethazine.
PizotifenThe risk or severity of adverse effects can be increased when Promethazine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Promethazine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Promethazine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Promethazine.
PractololPromethazine may increase the hypotensive activities of Practolol.
PramipexolePromethazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Promethazine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Promethazine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Promethazine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Promethazine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Promethazine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Promethazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Promethazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Promethazine.
PrimaquineThe serum concentration of Promethazine can be increased when it is combined with Primaquine.
PrimaquinePromethazine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Promethazine.
ProcainamidePromethazine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Promethazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Promethazine.
ProguanilThe serum concentration of Promethazine can be increased when it is combined with Proguanil.
PromazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Promazine.
PromazineThe metabolism of Promethazine can be decreased when combined with Promazine.
PropafenonePromethazine may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Promethazine.
PropericiazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Promethazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Promethazine.
PropranololPromethazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Promethazine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Promethazine.
PyrimethamineThe serum concentration of Promethazine can be increased when it is combined with Pyrimethamine.
QuazepamThe serum concentration of Promethazine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Promethazine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Promethazine is combined with Quetiapine.
QuinacrineThe serum concentration of Promethazine can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Promethazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Promethazine can be increased when it is combined with Quinine.
RadicicolThe serum concentration of Promethazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Promethazine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Promethazine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Promethazine.
RanolazineThe metabolism of Promethazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Promethazine is combined with Rasagiline.
RemifentanilPromethazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promethazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Promethazine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Promethazine is combined with Reserpine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Promethazine.
RifampicinThe metabolism of Promethazine can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Promethazine.
RisperidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Promethazine.
RitonavirThe metabolism of Promethazine can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Promethazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Promethazine.
RolapitantThe metabolism of Promethazine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Promethazine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Promethazine.
RopinirolePromethazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Promethazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Promethazine.
RotigotinePromethazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Promethazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Promethazine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Promethazine.
SaquinavirPromethazine may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promethazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promethazine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Promethazine.
SertindoleThe risk or severity of adverse effects can be increased when Promethazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Promethazine is combined with Sertraline.
SertralineThe metabolism of Promethazine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Promethazine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Promethazine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Promethazine.
SinefunginThe serum concentration of Promethazine can be increased when it is combined with Sinefungin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Promethazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Promethazine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Promethazine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Promethazine.
SorafenibThe metabolism of Promethazine can be decreased when combined with Sorafenib.
SotalolPromethazine may increase the hypotensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Promethazine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Promethazine.
StiripentolThe risk or severity of adverse effects can be increased when Promethazine is combined with Stiripentol.
SufentanilPromethazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine.
SulfadoxineThe serum concentration of Promethazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Promethazine can be increased when it is combined with Sulfametopyrazine.
SulfisoxazolePromethazine may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Promethazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Promethazine.
SuvorexantThe risk or severity of adverse effects can be increased when Promethazine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Promethazine.
tafenoquineThe serum concentration of Promethazine can be increased when it is combined with tafenoquine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Promethazine.
TapentadolPromethazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Promethazine.
TasimelteonThe risk or severity of adverse effects can be increased when Promethazine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Promethazine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Promethazine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Promethazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Promethazine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Promethazine.
TelavancinPromethazine may increase the QTc-prolonging activities of Telavancin.
TelithromycinPromethazine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Promethazine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Promethazine.
TerbinafineThe metabolism of Promethazine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Promethazine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Promethazine.
ThalidomidePromethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Promethazine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Promethazine.
ThiopentalThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Promethazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Promethazine.
ThiotepaThe metabolism of Promethazine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Promethazine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Promethazine.
TiclopidineThe metabolism of Promethazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Promethazine.
TimololPromethazine may increase the hypotensive activities of Timolol.
TipranavirThe metabolism of Promethazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Promethazine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Promethazine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Promethazine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Promethazine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Promethazine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Promethazine.
TramadolPromethazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Promethazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Promethazine.
TranylcypromineThe metabolism of Promethazine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Promethazine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Promethazine.
TrazodoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Promethazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Triflupromazine.
TrimethoprimThe serum concentration of Promethazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promethazine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Promethazine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Promethazine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Promethazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Promethazine.
VandetanibPromethazine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Promethazine.
VemurafenibPromethazine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Promethazine.
VenlafaxineThe metabolism of Promethazine can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Promethazine.
VigabatrinThe risk or severity of adverse effects can be increased when Promethazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Promethazine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Promethazine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Promethazine.
VortioxetineThe risk or severity of adverse effects can be increased when Promethazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Promethazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Promethazine.
ZiconotideThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Promethazine.
ZimelidineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Promethazine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Promethazine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promethazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Promethazine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Promethazine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Promethazine.
ZotepineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Promethazine is combined with Zuclopenthixol.
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K: Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. [PubMed:12657913 ]
  3. Smith BN, Armstrong WE: Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation. Neuroscience. 1993 Apr;53(3):855-64. [PubMed:8098142 ]
  4. Miller RA, Tu AT: Factors in snake venoms that increase capillary permeability. J Pharm Pharmacol. 1989 Nov;41(11):792-4. [PubMed:2576052 ]
  5. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. [PubMed:3011460 ]
  6. Ikeda H, Kubo N, Nakamura A, Harada N, Minamino M, Yamashita T: Histamine-induced calcium released from cultured human mucosal microvascular endothelial cells from nasal inferior turbinate. Acta Otolaryngol. 1997 Nov;117(6):864-70. [PubMed:9442829 ]
  7. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Bileviciute I, Stenfors C, Theodorsson E, Lundeberg T: Unilateral injection of calcitonin gene-related peptide (CGRP) induces bilateral oedema formation and release of CGRP-like immunoreactivity in the rat hindpaw. Br J Pharmacol. 1998 Nov;125(6):1304-12. [PubMed:9863661 ]
  2. Kelley BM, Porter JH: The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav. 1997 Aug;57(4):707-19. [PubMed:9258998 ]
  3. Hoenicke EM, Vanecek SA, Woods JH: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther. 1992 Oct;263(1):276-84. [PubMed:1403790 ]
  4. Martinez F, Coleman JW: A comparison of the effects of chlorpromazine and more selective histamine and 5-hydroxytryptamine antagonists on human IgG synthesis in vitro. Int J Immunopharmacol. 1990;12(2):185-91. [PubMed:2329012 ]
  5. Fiorella D, Rabin RA, Winter JC: The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl). 1995 Oct;121(3):347-56. [PubMed:8584617 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Cohen ME, Sharp GW, Donowitz M: Suggestion of a role for calmodulin and phosphorylation in regulation of rabbit ileal electrolyte transport: effects of promethazine. Am J Physiol. 1986 Nov;251(5 Pt 1):G710-7. [PubMed:3022601 ]
  2. Scott JA, Khaw BA, Fallon JT, Locke E, Rabito CA, Peto CA, Homcy CJ: The effect of phenothiazines upon maintenance of membrane integrity in the cultured myocardial cell. J Mol Cell Cardiol. 1986 Dec;18(12):1243-54. [PubMed:3820316 ]
  3. Lohr KM, Feix JB, Kurth C: Chlorpromazine inhibits neutrophil chemotaxis beyond the chemotactic receptor-ligand interaction. J Infect Dis. 1984 Nov;150(5):643-52. [PubMed:6092486 ]
  4. DiPaola M, Keith CH, Feldman D, Tycko B, Maxfield FR: Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides. J Cell Physiol. 1984 Feb;118(2):193-202. [PubMed:6319437 ]
  5. Luchowski EM, Yousif F, Triggle DJ, Maurer SC, Sarmiento JG, Janis RA: Effects of metal cations and calmodulin antagonists on [3H] nitrendipine binding in smooth and cardiac muscle. J Pharmacol Exp Ther. 1984 Sep;230(3):607-13. [PubMed:6433001 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Platts SH, Shi SJ, Meck JV: Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. [PubMed:16670408 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23